Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 5.


Attard, Gerhardt, Murphy, Laura, Clarke, Noel W, Cross, William, Jones, Robert J ORCID: 0000-0001-5608-001X, Parker, Christopher C, Gillessen, Silke, Cook, Adrian, Brawley, Chris, Amos, Claire L
et al (show 38 more authors) (2022) Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. LANCET, 399 (10323). pp. 447-460.


James, Nicholas D, Clarke, Noel W, Cook, Adrian, Ali, Adnan, Hoyle, Alex P, Attard, Gerhardt, Brawley, Christopher D, Chowdhury, Simon, Cross, William R, Dearnaley, David P
et al (show 46 more authors) (2022) Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). INTERNATIONAL JOURNAL OF CANCER, 151 (3). pp. 422-434.


Au, Lewis, Hatipoglu, Emine, Robert de Massy, Marc, Litchfield, Kevin, Beattie, Gordon, Rowan, Andrew, Schnidrig, Desiree, Thompson, Rachael, Byrne, Fiona, Horswell, Stuart
et al (show 195 more authors) (2021) Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. Cancer Cell, 39 (11). 1497-1518.e11.


James, Nicholas D, Ingleby, Fiona C, Clarke, Noel W, Amos, Claire L, Attard, Gerhardt, Brawley, Christopher D, Chowdhury, Simon, Cross, William, Dearnaley, David P, Gilbert, Duncan C
et al (show 37 more authors) (2022) Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial. JNCI cancer spectrum, 6 (4). pkac043-pkac043.


Gillessen, Silke, Bossi, Alberto, Davis, Ian D, de Bono, Johann ORCID: 0000-0002-2034-595X, Fizazi, Karim, James, Nicholas D ORCID: 0000-0002-7314-8204, Mottet, Nicolas, Shore, Neal, Small, Eric, Smith, Mathew
et al (show 108 more authors) (2023) Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. , Switzerland.

This list was generated on Sat Apr 6 11:32:28 2024 BST.